Vascepa also seems stalled. Its as if each side is trying to maintain the % of market. Generics do not want to increase share to avoid the appearance of infringement. AMRN does not want to increase market share to avoid decreasing generics' % of market share.
Or, the demand we hoped for is failing to come about. Seems odd the whole market has plateaued.
Market Data 
Markets 
AI
